Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) General Information
Description
Global rights to distribution of Camrelizumab for liver cancer.
Contact Information
Corporate Office
- Shanghai
- China
Corporate Office
- Shanghai
- China
Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) FAQs
-
Where is Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) headquartered?
Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) is headquartered in Shanghai, China.
-
What industry is Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) in?
Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab)’s primary industry is Buildings and Property.
-
Is Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) a private or public company?
Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) is a Private company.
-
What is Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab)’s current revenue?
The current revenue for Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) is .
-
Who are Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab)’s investors?
Jiangsu Hengrui Medicine has invested in Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab).
-
When was Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) acquired?
Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) was acquired on 06-Mar-2024.
-
Who acquired Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab)?
Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) was acquired by HLB (Holding Companies).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process